a month ago
GLTO
AnalystsBradley CaninoBradley Canino's Stock Forecasts
AnalystsBradley Canino
Sectors:
Analyst Ranking
Top 28%
#1449 out of 5177 analysts
Average Return
+2.69%
Win Rate
37%40 out of 109
Risk vs Reward
Poor
Good
Bradley Canino's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Summit Therapeutics IncSMMT | +441.18% | $3.74 | $20.24 | 2024-03-25 - 2025-03-25 | Strong Buy |
Celcuity IncCELC | +229.04% | $15.77 | $51.89 | 2024-08-14 - 2025-08-14 | Strong Buy |
Celcuity IncCELC | +213.06% | $15.27 | $47.81 | 2024-10-06 - 2025-10-06 | Strong Buy |
Olema Pharmaceuticals IncOLMA | +152.94% | $10.73 | $27.14 | 2025-10-07 - 2026-01-16 | Strong Buy |
Merus NvMRUS | +147.91% | $21.10 | $52.31 | 2023-10-23 - 2024-10-23 | Strong Buy |
Bradley Canino Analyst Color
Get additional color on Bradley Canino's coverage of popular stocks
2 months ago
NUVL
a year ago
SMMT
a year ago
NUVL
a year ago
SMMT
2 years ago
MRUS
2 years ago
CCCC
Bradley Canino's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Galecto IncGLTO | 2 | Strong Buy | $36.00 | +44.14% | Maintains | a month ago |
Janux Therapeutics IncJANX | 5 | Strong Buy | $38.00 | +176.16% | Maintains | a month ago |
Nuvalent IncNUVL | 5 | Strong Buy | $155.00 | +48.67% | Maintains | 2 months ago |
Pyxis Oncology IncPYXS | 3 | Strong Buy | $7.00 | +297.73% | Maintains | 2 months ago |
Kymera Therapeutics IncKYMR | 5 | Strong Buy | $90.00 | +29.42% | Assumes | 2 months ago |
Summit Therapeutics IncSMMT | 6 | Strong Buy | $40.00 | +134.74% | Reiterates | 3 months ago |
Cg Oncology IncCGON | 1 | Strong Buy | $90.00 | +64.44% | Initiates Coverage On | 3 months ago |
Olema Pharmaceuticals IncOLMA | 1 | Strong Buy | $20.00 | -26.31% | Initiates Coverage On | 3 months ago |
Celcuity IncCELC | 5 | Strong Buy | $110.00 | +2.84% | Initiates Coverage On | 4 months ago |
Syndax Pharmaceuticals IncSNDX | 7 | Strong Buy | $44.00 | +114.42% | Reinstates | 4 months ago |
Oric Pharmaceuticals IncORIC | 2 | Strong Buy | $18.00 | +48.51% | Assumes | 4 months ago |
Relay Therapeutics IncRLAY | 6 | Strong Buy | $15.00 | +104.08% | Assumes | 4 months ago |
C4 Therapeutics IncCCCC | 5 | Strong Buy | $8.00 | +258.74% | Initiates Coverage On | 4 months ago |
Black Diamond Therapeutics IncBDTX | 6 | Strong Buy | $8.00 | +212.50% | Initiates Coverage On | 4 months ago |
Alx Oncology Holdings IncALXO | 7 | Hold | $1.50 | +28.21% | Maintains | 10 months ago |
Cullinan Therapeutics IncCGEM | 2 | Strong Buy | $19.00 | +77.24% | Maintains | a year ago |
Arvinas IncARVN | 6 | Strong Buy | $51.00 | +318.03% | Maintains | a year ago |
Affimed NvAFMDQ | 6 | Hold | $4.00 | N/A | Maintains | a year ago |
Kura Oncology IncKURA | 6 | Hold | $19.00 | N/A | Downgrades | a year ago |
Zentalis Pharmaceuticals IncZNTL | 17 | Strong Buy | $10.00 | N/A | Maintains | 2 years ago |
Merus NvMRUS | 7 | Strong Buy | $99.00 | N/A | Maintains | 2 years ago |
Blueprint Medicines CorpBPMC | 6 | Strong Buy | $130.00 | N/A | Maintains | 2 years ago |
Deciphera Pharmaceuticals IncDCPH | 6 | Strong Buy | $23.00 | N/A | Maintains | 2 years ago |
Theseus Pharmaceuticals IncTHRX | 1 | Strong Buy | $24.00 | N/A | Initiates Coverage On | 3 years ago |
Turning Point Therapeutics IncTPTX | 2 | Hold | $45.00 | N/A | Maintains | 4 years ago |
Mersana Therapeutics IncMRSN | 1 | Hold | $450.00 | N/A | Initiates Coverage On | 5 years ago |
Seagen IncSGEN | 1 | Hold | $145.00 | N/A | Initiates Coverage On | 5 years ago |
Zymeworks IncZYME | 1 | Buy | $55.00 | N/A | Initiates Coverage On | 5 years ago |
Epizyme IncEPZM | 1 | Buy | $13.00 | N/A | Initiates Coverage On | 5 years ago |
Exelixis IncEXEL | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.